|
1
|
Fragomeni SM, Sciallis A and Jeruss JS:
Molecular subtypes and local-regional control of breast cancer.
Surg Oncol Clin N Am. 27:95–120. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Camorani S, Fedele M, Zannetti A and
Cerchia L: TNBC challenge: Oligonucleotide aptamers for new imaging
and therapy modalities. Pharmaceuticals (Basel). 11(pii): E1232018.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dent R, Trudeau M, Pritchard KI, Hanna WM,
Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA:
Triple-negative breast cancer: Clinical features and patterns of
recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
John EM, Hines LM, Phipps AI, Koo J,
Longacre TA, Ingles SA, Baumgartner KB, Slattery ML and Wu AH:
Reproductive history, breast-feeding and risk of triple negative
breast cancer: The Breast Cancer Etiology in Minorities (BEM)
study. Int J Cancer. 142:2273–2285. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Domagala P, Huzarski T, Lubinski J, Gugala
K and Domagala W: Immunophenotypic predictive profiling of
BRCA1-associated breast cancer. Virchows Arc. 458:55–64. 2011.
View Article : Google Scholar
|
|
6
|
Sameni M, Tovar EA, Essenburg CJ,
Chalasani A, Linklater ES, Borgman A, Cherba DM, Anbalagan A, Winn
ME, Graveel CR and Sloane BF: Cabozantinib (XL184) inhibits growth
and invasion of preclinical TNBC models. Clin Cancer Res.
22:923–934. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ouyang M, Li Y, Ye S, Ma J, Lu L, Lv W,
Chang G, Li X, Li Q, Wang S and Wang W: MicroRNA profiling implies
new markers of chemoresistance of triple-negative breast cancer.
PLoS One. 9:e962282014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
O'Shaughnessy J, Osborne C, Pippen JE,
Yoffe M, Patt D, Rocha C, Koo IC, Sherman BM and Bradley C:
Iniparib plus chemotherapy in metastatic triple-negative breast
cancer. N Engl J Med. 364:205–214. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ellis MJ and Perou CM: The genomic
landscape of breast cancer as a therapeutic roadmap. Cancer Discov.
3:27–34. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Altundag K: Is there a role of breast
pathologist in diagnostic challenges of discordances in ER, PR, and
HER2 between primary breast cancer and brain metastasis? J
Neurooncol. 138:2192018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dackus GMHE, Jozwiak K, Sonke GS, van der
Wall E, van Diest PJ, Hauptmann M, Siesling S and Linn SC: Optimal
adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by
age at diagnosis: A population-based cohort study. Eur J Cancer.
90:92–101. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jung J, Lee SH, Park M, Youn JH, Shin SH,
Gwak HS and Yoo H: Discordances in ER, PR, and HER2 between primary
breast cancer and brain metastasis. J Neurooncol. 137:295–302.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Di Leva G, Calin GA and Croce CM:
MicroRNAs: Fundamental facts and involvement in human diseases.
Birth Defects Res C Embryo Today. 78:180–189. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Calin GA, Dumitru CD, Shimizu M, Bichi R,
Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, et al:
Frequent deletions and down-regulation of micro-RNA genes miR15 and
miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci
USA. 99:15524–15529. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Michael MZ, SM OC, van Holst Pellekaan NG,
Young GP and James RJ: Reduced accumulation of specific microRNAs
in colorectal neoplasia. Mol Cancer Res. 1:882–891. 2003.PubMed/NCBI
|
|
16
|
Takamizawa J, Konishi H, Yanagisawa K,
Tomida S, Osada H, Endoh H, Harano T, Yatabe Y, Nagino M, Nimura Y,
et al: Reduced expression of the let-7 microRNAs in human lung
cancers in association with shortened postoperative survival.
Cancer Res. 64:3753–3756. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Metzler M, Wilda M, Busch K, Viehmann S
and Borkhardt A: High expression of precursor microRNA-155/BIC RNA
in children with Burkitt lymphoma. Genes Chromosomes Cancer.
39:167–169. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Eis PS, Tam W, Sun L, Chadburn A, Li Z,
Gomez MF, Lund E and Dahlberg JE: Accumulation of miR-155 and BIC
RNA in human B cell lymphomas. Proc Natl Acad Sci USA.
102:3627–3632. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Singh R and Mo YY: Role of microRNAs in
breast cancer. Cancer Biol Ther. 14:201–212. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Deng Y, Bi X, Zhou H, You Z, Wang Y, Gu P
and Fan X: Repair of critical-sized bone defects with
anti-miR-31-expressing bone marrow stromal stem cells and
poly(glycerol sebacate) scaffolds. Eur Cell Mater. 27:13–25. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Stepicheva NA and Song JL: Function and
regulation of microRNA-31 in development and disease. Mol Reprod
Dev. 83:654–674. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Huang S, Chen Z, Wu W, Wang M, Wang R, Cui
J, Li W and Wang S: MicroRNA-31 promotes arterial smooth muscle
cell proliferation and migration by targeting mitofusin-2 in
arteriosclerosis obliterans of the lower extremitie. Exp Ther Med.
15:633–640. 2018.PubMed/NCBI
|
|
23
|
Munoz X, Mata A, Bassas L and Larriba S:
Altered miRNA signature of developing germ-cells in infertile
patients relates to the severity of spermatogenic failure and
persists in spermatozoa. Sci Rep. 5:179912015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kresowik JD, Devor EJ, Van Voorhis BJ and
Leslie KK: MicroRNA-31 is significantly elevated in both human
endometrium and serum during the window of implantation: A
potential biomarker for optimum receptivity. Biol Reprod.
91:172014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Augoff K, Das M, Bialkowska K, McCue B,
Plow EF and Sossey-Alaoui K: miR-31 is a broad regulator of
β1-integrin expression and function in cancer cells. Mol Cancer
Res. 9:1500–1508. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yamagishi M, Nakano K, Miyake A, Yamochi
T, Kagami Y, Tsutsumi A, Matsuda Y, Sato-Otsubo A, Muto S,
Utsunomiya A, et al: Polycomb-mediated loss of miR-31 activates
NIK-dependent NF-kappaB pathway in adult T cell leukemia and other
cancers. Cancer Cell. 21:121–135. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kim HS, Lee KS, Bae HJ, Eun JW, Shen Q,
Park SJ, Shin WC, Yang HD, Park M, Park WS, et al: MicroRNA-31
functions as a tumor suppressor by regulating cell cycle and
epithelial-mesenchymal transition regulatory proteins in liver
cancer. Oncotarget. 6:8089–8102. 2015.PubMed/NCBI
|
|
28
|
Cottonham CL, Kaneko S and Xu L: miR-21
and miR-31 converge on TIAM1 to regulate migration and invasion of
colon carcinoma cells. J Biol Chem. 285:35293–35302. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xu RS, Wu XD, Zhang SQ, Li CF, Yang L, Li
DD, Zhang BG, Zhang Y, Jin JP and Zhang B: The tumor suppressor
gene RhoBTB1 is a novel target of miR-31 in human colon cancer. Int
J Oncol. 42:676–682. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu CJ, Tsai MM, Hung PS, Kao SY, Liu TY,
Wu KJ, Chiou SH, Lin SC and Chang KW: miR-31 ablates expression of
the HIF regulatory factor FIH to activate the HIF pathway in head
and neck carcinoma. Cancer Res. 70:1635–1644. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yu M, Liang H, Fu Z, Wang X, Liao Z, Zhou
Y, Liu Y, Wang Y, Hong Y, Zhou X, et al: BAP1 suppresses lung
cancer progression and is inhibited by miR-31. Oncotarget.
7:13742–13753. 2016.PubMed/NCBI
|
|
32
|
Korner C, Keklikoglou I, Bender C, Worner
A, Munstermann E and Wiemann S: MicroRNA-31 sensitizes human breast
cells to apoptosis by direct targeting of protein kinase C epsilon
(PKCepsilon). J Biol Chem. 288:8750–8761. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Park JH, Ahn JH and Kim SB: How shall we
treat early triple-negative breast cancer (TNBC): From the current
standard to upcoming immuno-molecular strategies. ESMO Open. 3
(Suppl 1):e0003572018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Siddiqui WA, Ahad A and Ahsan H: The
mystery of BCL2 family: Bcl-2 proteins and apoptosis: An update.
Arch Toxicol. 89:289–317. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lin Y, Kokontis J, Tang F, Godfrey B, Liao
S, Lin A, Chen Y and Xiang J: Androgen and its receptor promote
Bax-mediated apoptosis. Mol Cell Biol. 26:1908–1916. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ge C, Cao B, Feng D, Zhou F, Zhang J, Yang
N, Feng S, Wang G and Aa J: The down-regulation of SLC7A11 enhances
ROS induced P-gp over-expression and drug resistance in MCF-7
breast cancer cells. Sci Rep. 7:37912017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Paplomata E and O'Regan R: The
PI3K/AKT/mTOR pathway in breast cancer: Targets, trials and
biomarkers. Ther Adv Med Oncol. 6:154–166. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Henley D, Isbill M, Fernando R, Foster JS
and Wimalasena J: Paclitaxel induced apoptosis in breast cancer
cells requires cell cycle transit but not Cdc2 activity. Cancer
Chemother Pharmacol. 59:235–249. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Tan M and Yu D: Molecular mechanisms of
erbB2-mediated breast cancer chemoresistance. Adv Exp Med Biol.
608:119–129. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Orr GA, Verdier-Pinard P, McDaid H and
Horwitz SB: Mechanisms of Taxol resistance related to microtubules.
Oncogene. 22:7280–7295. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Frankel A, Buckman R and Kerbel RS:
Abrogation of taxol-induced G2-M arrest and apoptosis in human
ovarian cancer cells grown as multicellular tumor spheroids. Cancer
Res. 57:2388–2393. 1997.PubMed/NCBI
|
|
43
|
Yin S, Bhattacharya R and Cabral F: Human
mutations that confer paclitaxel resistance. Mol Cancer Ther.
9:327–335. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Tsimberidou AM, Braiteh F, Stewart DJ and
Kurzrock R: Ultimate fate of oncology drugs approved by the us food
and drug administration without a randomized Trial. J Clin Oncol.
27:6243–6250. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Song G, Ouyang G and Bao S: The activation
of Akt/PKB signaling pathway and cell survival. J Cell Mol Med.
9:59–71. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wang YP, Huang LY, Sun WM, Zhang ZZ, Fang
JZ, Wei BF, Wu BH and Han ZG: Insulin receptor tyrosine kinase
substrate activates EGFR/ERK signalling pathway and promotes cell
proliferation of hepatocellular carcinoma. Cancer Lett. 337:96–106.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Tokunaga E, Kimura Y, Mashino K, Oki E,
Kataoka A, Ohno S, Morita M, Kakeji Y, Baba H and Maehara Y:
Activation of PI3K/Akt signaling and hormone resistance in breast
cancer. Breast Cancer. 13:137–144. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Clark AS, West K, Streicher S and Dennis
PA: Constitutive and inducible Akt activity promotes resistance to
chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol
Cancer Ther. 1:707–717. 2002.PubMed/NCBI
|
